Skip to main content

Talquetamab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 12, 2024.

Applies to the following strengths: tgvs 2 mg/mL; tgvs 40 mg/mL

Usual Adult Dose for Multiple Myeloma

WEEKLY DOSING SCHEDULE:
Step-Up Dose 1: Administer 0.01 mg/kg subcutaneously on Day 1.
Step-Up Dose 2: Administer 0.06 mg/kg subcutaneously on Day 4.
First Treatment Dose: Administer 0.4 mg/kg subcutaneously on Day 7, and then weekly thereafter.


BI-WEEKLY (EVERY 2 WEEKS) DOSING SCHEDULE
Step-Up Dose 1: Administer 0.01 mg/kg subcutaneously on Day 1.
Step-Up Dose 2: Administer 0.06 mg/kg subcutaneously on Day 4.
Step-Up Dose 3: Administer 0.4 mg/kg subcutaneously on Day 7.
First Treatment Dose: Administer 0.8 mg/kg subcutaneously on Day 10, and then every 2 weeks thereafter.

RECOMMENDED PRETREATMENT MEDICATIONS DURING STEP-UP DOSING:
Administer the Following Medications 1 to 3 Hours Before Each Step-Up Dose:

Comments:

Use: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Renal Dose Adjustments

Liver Dose Adjustments

Dose Adjustments

Restarting This Drug After Dosage Delay:


WEEKLY DOSING SCHEDULE AFTER DOSE DELAY:
Last dose: 0.01 mg/kg, and time since last dose given is more than 7 days:

Last dose: 0.06 mg/kg, and time from last dose administered is:

Last dose: 0.4 mg/kg, and time from last dose administered is:

BI-WEEKLY (EVERY 2 WEEKS) DOSING SCHEDULE AFTER DOSE DELAY:
Last dose: 0.01 mg/kg, and time since last dose given is more than 7 days:

Last dose: 0.06 mg/kg, and time from last dose administered is:

Last dose: 0.4 mg/kg, and time from last dose administered is:

Last dose: 0.8 mg/kg, and time from last dose administered is:

Adverse Reaction Dose Modifications:
CYTOKINE RELEASE SYNDROME (CRS):
If CRS is suspected, withhold therapy and institute appropriate treatment.
Grade 1:
Grade 2:
Grade 3:
Grade 4:

NEUROLOGIC TOXICITY:
Grade 1:
Grade 2; Grade 3 (First Occurrence):
Grade 3 (Recurrent) or Grade 4:

IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS):
Grade 1:
Grade 2
Grade 3 (First Occurrence):
Grade 3 (Recurrent):
Grade 4:

ORAL TOXICITY AND WEIGHT LOSS:
Grades 1 to 2:
Grade 3:
Grade 4:

INFECTIONS:
All Grades:
Grade 3:
Grade 4:

CYTOPENIAS:
Absolute Neutrophil Count (ANC) Less Than 0.5 x 10(9)/L:
Febrile Neutropenia:
Hemoglobin Less Than 8 g/dL:
Platelet Count Less Than 25,000/mcL OR Platelet Count Between 25,000 to 50,000/mcL With Bleeding:

SKIN REACTIONS:
Grade 3 to 4:

OTHER NON-HEMATOLOGIC ADVERSE REACTIONS:
Grade 3:
Grade 4:

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for talquetamab. It includes a communication plan, elements to assure safe use, and implementation system. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNINGS:


CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Preparation techniques:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.